Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria

American Journal of Respiratory and Critical Care Medicine - United States
doi 10.1164/rccm.201602-0402oc
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Thoracic Society

Related search

Diagnostic Criteria for Idiopathic Pulmonary Fibrosis

Lancet Respiratory Medicine,The
PulmonaryRespiratory Medicine
2018English

Psy54 - Budget Impact Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in Turkey

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Efficacy and Safety of Nintedanib in Patients With Advanced Idiopathic Pulmonary Fibrosis

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2020English

Remarkable Improvement in a Patient With Idiopathic Pulmonary Fibrosis After Treatment With Nintedanib

Internal Medicine
Internal MedicineMedicine
2019English

Psy105 - Cost-Utility of Nintedanib Versus Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis: A Belgian Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Idiopathic Pulmonary Fibrosis

Pulmonologiya
PulmonaryRespiratory Medicine
2015English

Idiopathic Pulmonary Fibrosis

2020English

Epigenomics of Idiopathic Pulmonary Fibrosis

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2012English

The Pathogenesis of Idiopathic Pulmonary Fibrosis

Therapeutic Advances in Respiratory Disease
PulmonaryRespiratory MedicinePharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy